Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Motilal Oswal Securities Ltd.
$81.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sun Pharmaceutical Industries Ltd's Subsidiary And Intrexon Form Joint Venture To Develop New Class Of Therapeutics For Ocular Diseases


Tuesday, 1 Oct 2013 07:21am EDT 

Sun Pharmaceutical Industries Ltd, through its subsidiary and Intrexon Corp announced the formation of joint venture to develop controllable gene-based therapics for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. The joint venture will leverage Sun Pharma's global capabilities and experience in developing and manufacturing complex dosage forms and specialty pharmaceuticals for niche therapy areas. Intrexon and Sun Pharma will share in both the financing of, and the revenues from, the joint venture. Through an exclusive channel collaboration (ECC), the joint venture will have access to Intrexon's full suite of synthetic biology technologies, including the RheoSwitch Therapeutic System (RTS) platform.